Indeed, membrane localization of CA9, which allows its targeting by both small molecule inhibitors and monoclonal antibodies, together with the availability of specific FDA-approved inhibitors [40], strengthened our choice to consider this protein as a valuable target for a possible novel NB therapy. Here, CA9 is linked to neuroblastoma.